Skip to content
Senseonics, Incorporated logo — Advancing the future of diabetes management through innovati...

Senseonics, Incorporated

Advancing the future of diabetes management through innovative technology.

Founded 1996 United States Germantown, United States 280 employees IPO Total: $634.30M Biotechnology, Hardware +3

General Information

Company Name Senseonics, Incorporated
Founded Year 1996
Location United States Germantown, United States
Founders / Decision Makers
Team member Team member Team member Team member Team member
Employees 280
Industries Biotechnology, Hardware, Health Care +2
Funding Stage IPO
Business Model B2B2C, B2B
Revenue Model Product Sales, Subscription
Social

BounceWatch is an independent company data service, not affiliated with Senseonics, Incorporated. To contact Senseonics, Incorporated, visit senseonics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Senseonics, Incorporated compare?

A PDF of Senseonics, Incorporated and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Senseonics, Incorporated soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Senseonics, Incorporated

Senseonics, Incorporated, founded in 1996, is a pioneering force in the biotechnology and medical devices industries, with a focal aim of revolutionizing diabetes management through advanced continuous glucose monitoring (CGM) technologies. Their implantable CGM systems offer individuals with diabetes enhanced confidence and control over their health, epitomizing their slogan: "Advancing the future of diabetes management through innovative technology."

Based in the United States, Senseonics thrives on collaboration and innovation. By integrating efforts across science, engineering, and clinical teams, the company addresses real-world diabetes challenges, delivering solutions with profound impact. The culture of cross-functional teamwork fuels their groundbreaking progress.

In terms of financial backing, Senseonics secured a substantial $92.00M in post-IPO debt investment on 01 May 2026, with financing led by Barclays, Lake Street Capital, and Mizuho. This robust financial endorsement underscores investor confidence in their mission and potential growth trajectory.

Business keywords: diabetes management, continuous glucose monitoring, CGM technology, implantable devices, glucose sensor innovation, medical device startup, fluorescence sensing technology, long-term monitoring, diabetes care solutions, healthcare collaboration, breakthrough technology, health tech R&D, sensor life stability

Services & Products

Development of Long-term Implantable Continuous Glucose Monitoring Systems
Conducting Medical Research and Clinical Studies
Providing Innovative Diabetes Management Solutions

Target Customers

Diabetic Patients Healthcare Providers Clinics and Hospitals Endocrinologists

Funding Rounds & Investors (17)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt $92.00M 3
Barclays, Lake Street Capital +1
01 May 2026
Post-IPO Equity $25.00M -
01 May 2025
Post-IPO Equity $16.00M -
01 Oct 2024
Post-IPO Debt $50.00M 1
Hercules Capital
01 Sep 2023
Post-IPO Equity $50.00M -
01 Jan 2021
Post-IPO Debt $35.00M 1
Phc
01 Aug 2020
Post-IPO Debt $45.00M -
01 Jan 2019
Post-IPO Equity $150.00M -
01 Jun 2018
Post-IPO Equity $41.00M 1
NEA
01 May 2017
IPO $45.00M -
01 Apr 2016

View All 17 Funding Rounds

Senseonics, Incorporated Alternatives & Competitors

View All Alternatives
Senseonics, Incorporated vs

At GlySens®, we are dedicated to advancing the care of individuals with diabetes through the develop...

Series D
5 employees
Health Care, Manufacturing
Senseonics, Incorporated vs
Echo Therapeutics
Echo Therapeutics United States

Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) syst...

Post-IPO Debt
8 employees
Biotechnology, Health Care
Senseonics, Incorporated vs
Apollon
Apollon Korea South

The wearable that reads your glucose

Seed
40 employees
Biotechnology, Health Care

FAQ About Senseonics, Incorporated

Advancing the future of diabetes management through innovative technology.
Senseonics, Incorporated was founded in 1996.
Senseonics, Incorporated is headquartered in Germantown, United States.
Senseonics, Incorporated operates in Biotechnology, Hardware, Health Care, Medical Devices and Autonomous and Sensor Tech. Its work centres on diabetes management, continuous glucose monitoring, CGM technology and implantable devices. Its customers include Diabetic Patients, Healthcare Providers and Clinics and Hospitals.
Senseonics, Incorporated has a B2B2C and B2B business model. Its revenue comes from Product Sales and Subscription.
Senseonics, Incorporated has approximately 280 employees.
Senseonics, Incorporated has completed 17 funding rounds, raising a total of $634.30M. The latest funding stage is IPO.
Senseonics, Incorporated offers: Development of Long-term Implantable Continuous Glucose Monitoring Systems, Conducting Medical Research and Clinical Studies, Providing Innovative Diabetes Management Solutions.
Top alternatives and competitors to Senseonics, Incorporated include GlySens Incorporated, Echo Therapeutics, Apollon, GraphWear Technologies Inc., Lifecare. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Senseonics, Incorporated and GlySens Incorporated are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Senseonics, Incorporated, https://bouncewatch.com/company/senseonics-incorporated, updated 6 August 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout